Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Rémy Nicolle

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8084-1173; OpenAlex author ID A5030107635. Sources: OpenAlex.

Their work

Papers
52 (first author 6, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
188
Papers, trials and grants by year

2017: 2 papers · 2018: 2 papers · 2019: 3 papers · 2020: 2 papers · 2021: 12 papers · 2022: 7 papers · 2023: 6 papers · 2024: 8 papers · 2025: 3 papers · 2026: 7 papers

Papers 50 of 52

  1. Decoding the Integrated Stress Response of Pancreatic Cancer: Identifying a Serine-dependent Tumor Subset Under Metabolic Relationships With CAFs. Co-author DOI 10.1002/advs.202515740↗
  2. DNA methylation-based classification uncovers acinar and ductal origins for KPC-derived PDAC cell lines. Co-author DOI 10.1016/j.canlet.2026.218666↗
  3. Prognostic and predictive values of transcriptomic signatures in metastatic pancreatic cancer: A biomarker analysis of three French multicenter prospective ran… First author DOI 10.1016/j.canlet.2026.218745↗
  4. Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX followed by high-dose stereotactic body radiotherapy. Co-author DOI 10.1038/s41416-025-03274-0↗
  5. Deep Learning of Histopathology Predicts Outcomes After Surgery for Pancreatic Cancer. Co-author DOI 10.1200/cci-25-00268↗
  6. Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study. Co-author DOI 10.1200/jco-25-02508↗
  7. Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. Last author DOI 10.1200/jco-26-00327↗
  8. Redefining phenotypic intratumor heterogeneity of pancreatic ductal adenocarcinoma: a bottom-up approach. Co-author DOI 10.1002/path.6398↗
  9. Medical management of pancreatic cancer: from personalization to broadening treatment strategies. Co-author DOI 10.1016/j.ctrv.2025.102973↗
  10. Glycation Stress–Driven Transcriptomic Signature Predicts Survival Benefit from Adjuvant Gemcitabine in Resectable Pancreatic Cancer Co-author DOI 10.1101/2025.07.07.663493↗
  11. High-resolution and quantitative spatial analysis reveal intra-ductal phenotypic and functional diversification in pancreatic cancer. Co-author DOI 10.1002/path.6212↗
  12. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.annonc.2024.06.010↗
  13. Predictive genomic and transcriptomic analysis on endoscopic ultrasound-guided fine needle aspiration materials from primary pancreatic adenocarcinoma: a prosp… Co-author DOI 10.1016/j.ebiom.2024.105373↗
  14. Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41591-023-02790-x↗
  15. Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2024.05.032↗
  16. Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after Total Neoadjuvant Therapy including Stereotactic Body Radiotherapy Co-author DOI 10.1101/2024.04.30.591890↗
  17. KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment. Co-author DOI 10.1158/1078-0432.ccr-23-1421↗
  18. Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CC… Co-author DOI 10.1200/jco.22.02668↗
  19. Trop-2 is a ubiquitous and promising target in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.clinre.2023.102108↗
  20. Priming therapy by targeting enhancer-initiated pathways in patient-derived pancreatic cancer cells. Co-author DOI 10.1016/j.ebiom.2023.104602↗
  21. The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy. Co-author DOI 10.1016/s2468-1253(23)00207-8↗
  22. Pacpaint: a histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinoma. Co-author DOI 10.1038/s41467-023-39026-y↗
  23. A Transcriptomic-Based Tool to Predict Gemcitabine Sensitivity in Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2022.11.035↗
  24. Neutrophil-derived complement factor P induces cytotoxicity in basal-like cells via caspase 3/7 activation in pancreatic cancer Co-author DOI 10.1101/2023.10.28.564512↗
  25. Periostin- and podoplanin-positive cancer-associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenoc… First author DOI 10.1002/path.6011↗
  26. Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic c… Co-author DOI 10.1016/j.tranon.2021.101315↗
  27. Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction. Co-author DOI 10.1038/s41698-022-00299-z↗
  28. PACpAInt: a deep learning approach to identify molecular subtypes of pancreatic adenocarcinoma on histology slides Co-author DOI 10.1101/2022.01.04.474951↗
  29. Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies. Co-author DOI 10.1177/17588359221118019↗
  30. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Co-author DOI 10.3390/cancers14174265↗
  31. Correction: Ponzo et al. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Cancers 2022, 14, 4265. Co-author DOI 10.3390/cancers14246160↗
  32. A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.annonc.2020.10.601↗
  33. Microbiome and pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.clinre.2020.101589↗
  34. A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis. Co-author DOI 10.1016/j.ebiom.2021.103541↗
  35. Tumour and stroma RNA signatures predict more accurately distant recurrence than clinicopathological factors in resected pancreatic adenocarcinoma. Last author DOI 10.1016/j.ejca.2021.01.042↗
  36. Squamousness gain defines pancreatic ductal adenocarcinoma hepatic metastases phenotype, and gemcitabine response. Co-author DOI 10.1016/j.ejca.2021.06.038↗
  37. Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With Macrophages. Co-author DOI 10.1016/j.jcmgh.2021.01.008↗
  38. Translatome-based classification reveals a dual metabolic dependency of a new tumor subtype of pancreatic cancer First author DOI 10.1016/j.pan.2021.05.117↗
  39. Pancreatic cancer prognosis is predicted by an ATAC-array technology for assessing chromatin accessibility. Co-author DOI 10.1038/s41467-021-23237-2↗
  40. Prognostic Relevance of Pancreatic Adenocarcinoma Whole-Tumor Transcriptomic Subtypes and Components. First author DOI 10.1158/1078-0432.ccr-21-1907↗
  41. Pancreatic Cancer Meets Human Microbiota: Close Encounters of the Third Kind. First author DOI 10.3390/cancers13061231↗
  42. Pancreatic Ductal Adenocarcinoma Arising in Young and Old Patients Displays Similar Molecular Features. Co-author DOI 10.3390/cancers13061234↗
  43. Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models. Co-author DOI 10.3390/cancers13102473↗
  44. Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2020.102858↗
  45. Basal-like and classical cells coexist in pancreatic cancer revealed by single-cell analysis on biopsy-derived pancreatic cancer organoids from the classical s… Co-author DOI 10.1096/fj.202000363rr↗
  46. Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications. Co-author DOI 10.1093/annonc/mdz181↗
  47. Prognostic Biomarkers in Pancreatic Cancer: Avoiding Errata When Using the TCGA Dataset. Co-author DOI 10.3390/cancers11010126↗
  48. hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status. First author DOI 10.3390/cancers11111808↗
  49. Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. Co-author DOI 10.1038/s41467-018-04383-6↗
  50. [Multi-omic approaches reveal new therapeutic targets for the treatment of pancreatic cancer]. Co-author DOI 10.1051/medsci/20183405003↗

Closest collaborators

The 25 strongest of 188 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jerome F. Cros · 27 shared papers, 2019–2026 · strength 4.02
  2. Nelson Dusetti · 26 shared papers, 2017–2026 · strength 3.52
  3. Juan Iovanna · 23 shared papers, 2017–2026 · strength 3.00
  4. Jean‐Baptiste Bachet · 19 shared papers, 2019–2026 · strength 2.94
  5. Pascal R. Hammel · 14 shared papers, 2021–2026 · strength 2.19
  6. Cindy Neuzillet · 11 shared papers, 2021–2026 · strength 1.71
  7. Louis de Mestier · 10 shared papers, 2019–2026 · strength 1.60
  8. Vinciane Rebours · 10 shared papers, 2021–2026 · strength 1.50
  9. Jean‐Luc Van Laethem · 9 shared papers, 2019–2026 · strength 1.32
  10. Nicolas Alejandro Fraunhoffer · 8 shared papers, 2021–2026 · strength 1.24
  11. Tatjana Arsenijevic · 8 shared papers, 2021–2026 · strength 1.22
  12. Magali Svrcek · 10 shared papers, 2019–2024 · strength 1.20
  13. Thierry Conroy · 6 shared papers, 2024–2026 · strength 1.15
  14. Anthony Turpin · 6 shared papers, 2022–2026 · strength 1.12
  15. James Biagi · 5 shared papers, 2024–2026 · strength 0.95
  16. Odile Gayet · 10 shared papers, 2017–2022 · strength 0.93
  17. Christelle Bouchart · 5 shared papers, 2021–2026 · strength 0.89
  18. Shulin Zhao · 5 shared papers, 2021–2026 · strength 0.87
  19. Julie Roques · 8 shared papers, 2017–2022 · strength 0.82
  20. Jérôme Raffenne · 7 shared papers, 2019–2025 · strength 0.82
  21. Marc Hilmi · 5 shared papers, 2021–2025 · strength 0.81
  22. Emmanuel Mitry · 5 shared papers, 2022–2026 · strength 0.77
  23. Francesco Puleo · 7 shared papers, 2019–2022 · strength 0.76
  24. Corinne Bousquet · 6 shared papers, 2021–2026 · strength 0.76
  25. Aurélien Lambert · 4 shared papers, 2024–2026 · strength 0.74

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.